Ignite Creation Date:
2025-12-25 @ 4:02 AM
Ignite Modification Date:
2025-12-26 @ 2:55 AM
Study NCT ID:
NCT00128102
Status:
COMPLETED
Last Update Posted:
2020-10-26
First Post:
2005-08-05
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-06-30
Start Date Type:
ACTUAL
Primary Completion Date:
2011-07-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-11-21
Completion Date Type:
ACTUAL
First Submit Date:
2005-08-05
First Submit QC Date:
None
Study First Post Date:
2005-08-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-10-01
Results First Submit QC Date:
None
Results First Post Date:
2020-10-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-10-01
Last Update Post Date:
2020-10-26
Last Update Post Date Type:
ACTUAL